arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Cogent Biosciences, Inc.

COGT
$29.55 ▼ -1.92 (-6.10%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
39 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cogent Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $5.1B
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -10.7% ↘
FCF / Share $-0.45 ↗
Trailing P/E —
Price / Book 9.5x
FCF Yield —
Debt / Equity 0.42
info Valuation on last close. End-of-day price, Nov 5, 2026.

39-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$312.00K
↓ -69.4% —
Net Income Profit after all expenses
$-97.35M
↓ -35.2% —
Operating Margin Operating profit as % of sales
-87.3%
↑ +74.0% —
FCF / Share Free cash flow per share
$-0.45
↑ +15.7% —
Long-Term Debt Long-term obligations
$223.46M
— +0.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
16
Financial Health
35
Cash Quality →
54

bar_chart Data from SEC EDGAR XBRL filings

Synced 6 days ago 10 years · 39 quarters